These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 18033315

  • 21. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, Young J, Zhao S, Wang Y, Kopinja J, Qu X, Reilly J, Walker D, Xu L, Aleksandrowicz D, Marshall G, Scott ML, Kohl NE, Bachman E.
    Biochem Pharmacol; 2009 Aug 15; 78(4):382-9. PubMed ID: 19413997
    [Abstract] [Full Text] [Related]

  • 22. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 23. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P.
    Hum Pathol; 2006 Nov 20; 37(11):1458-64. PubMed ID: 16949922
    [Abstract] [Full Text] [Related]

  • 24. Aberrant signal transduction pathways in myeloproliferative neoplasms.
    Kota J, Caceres N, Constantinescu SN.
    Leukemia; 2008 Oct 20; 22(10):1828-40. PubMed ID: 18769448
    [Abstract] [Full Text] [Related]

  • 25. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb 20; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 26. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
    Kreft A, Kindler T, Springer E, Kirkpatrick CJ.
    Virchows Arch; 2011 Nov 20; 459(5):521-7. PubMed ID: 22006129
    [Abstract] [Full Text] [Related]

  • 27. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 20; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 28. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J, Fijnheer R, Walsh IB, Hermans MH.
    Hematol Oncol; 2006 Dec 20; 24(4):227-33. PubMed ID: 17006961
    [Abstract] [Full Text] [Related]

  • 29. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH, Park TS, Maeng HY, Sun YK, Kim YA, Kie JH, Cho EH, Song J, Lee KA, Suh B, Choi JR.
    Cancer Genet Cytogenet; 2009 Feb 20; 189(1):43-7. PubMed ID: 19167611
    [Abstract] [Full Text] [Related]

  • 30. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K, Kodama A, Ohyashiki JH.
    Cancer Genet Cytogenet; 2008 Oct 20; 186(1):6-11. PubMed ID: 18786436
    [Abstract] [Full Text] [Related]

  • 31. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Oct 20; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 32. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.
    Int J Hematol; 2007 Aug 20; 86(2):130-6. PubMed ID: 17875526
    [Abstract] [Full Text] [Related]

  • 33. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
    Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.
    Appl Immunohistochem Mol Morphol; 2014 Oct 20; 22(9):663-8. PubMed ID: 24897074
    [Abstract] [Full Text] [Related]

  • 34. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.
    Am J Surg Pathol; 2007 Feb 20; 31(2):233-9. PubMed ID: 17255768
    [Abstract] [Full Text] [Related]

  • 35. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar 20; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 36. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P, Hanrahan V, Baker B, Romeril K.
    Am J Hematol; 2007 Jan 20; 82(1):80-2. PubMed ID: 16924638
    [Abstract] [Full Text] [Related]

  • 37. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST, Gotlib J.
    Expert Rev Hematol; 2010 Jun 20; 3(3):323-37. PubMed ID: 21082983
    [Abstract] [Full Text] [Related]

  • 38. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 20; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [Abstract] [Full Text] [Related]

  • 39. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG, Tognon R, Nunes NS, Rodrigues LC, Ferreira AF, Kashima S, Covas DT, Santana M, Souto EX, Perobelli L, Simões BP, Dias-Baruffi M, Castro FA.
    J Clin Pathol; 2016 Oct 20; 69(10):926-9. PubMed ID: 27402956
    [Abstract] [Full Text] [Related]

  • 40. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2016 Oct 20; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.